A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.
Epistemonikos ID: ad98e9f1cb31c984a93059c9b972a4706822137b
First added on: Nov 14, 2017